When was Triveni Bio founded?

Triveni Bio was founded in 2023 and raised its 1st funding round within a year of its incorporation.

Where is Triveni Bio located?

Triveni Bio is headquartered in Watertown, United States.

How many employees does Triveni Bio have?

As of Jul 31, 2026, the latest employee count at Triveni Bio is 57.

Is Triveni Bio a funded company?

Triveni Bio is a funded company, having raised a total of $272M across 3 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Oct 26, 2023.

When was the latest funding round of Triveni Bio?

Triveni Bio's latest funding was a $***** Series C round on Jun 17, 2026, with participation from 3 investors.

Where does Triveni Bio rank among its competitors?

Triveni Bio ranks 68th amongst 586 active competitors, of which 189 are funded. It stands 4th in terms of total funding among its competitors. The most recent competitor to raise funding was Triveni Bio, which secured $65M in Jun, 2026.

Who are the top competitors of Triveni Bio?

Triveni Bio's top competitors include BeiGene, Biogen and argenx. Among them, Triveni Bio secured the most recent funding round in June, 2026.

Triveni Bio - 2026 Company Profile, Team, Funding & Competitors

Triveni Bio is a series C company based in Watertown (United States), founded in 2023. It operates as a Developer of functional antibodies for the treatment of immunological and inflammatory disorders. Triveni Bio has raised $272M in funding from investors like Atlas Venture, Goldman Sachs and Janus Henderson Investors. The company has 586 active competitors, including 189 funded and 168 that have exited. Its top competitors include companies like BeiGene, Biogen and argenx.

Company Details

Developer of functional antibodies for the treatment of immunological and inflammatory disorders. The company is pioneering a mendelian genetics-informed precision medicine which includes TRIV-509 that targets kallikreins 5 and 7 (KLK5/7), promising targets for the treatment of atopic dermatitis, asthma, and other inflammatory indications.

Website: triveni.bio
Email ID: *****@triveni.bio

Key Metrics

Founded Year

2023

Location

Watertown, United States

Stage

Series C

Total Funding

$272M in 3 rounds

Latest Funding Round

Series C, Jun 17, 2026, $*****

Investors

Atlas Venture & 11 more

Ranked

68^th among 586 active competitors

Employee Count

57 as on Jul 31, 2026

Similar Companies

BeiGene & 696 more

View Triveni Bio's full profile

Triveni Bio has raised a total funding of $272M over 3 rounds. Its first funding round was on Oct 26, 2023. Its latest funding round was a Series C round on Jun 17, 2026 for $*****. 3 investors participated in its latest round. Triveni Bio has 12 institutional investors.

Here is the list of recent funding rounds of Triveni Bio:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jun 17, 2026	6674896	Series C	9200274	2137643	5499248	5203422
Oct 02, 2024	7334590	Series B	6188212	8567691	6282338	Fidelity Investments & 6 more
Oct 26, 2023	6228654	Series A	8558396	6820514	Atlas Venture & 1 more	Orbimed & 4 more

Access funding benchmarks and valuations. Sign up today!

View details of Triveni Bio's funding rounds and investors

Triveni Bio's employee count trend

Triveni Bio has 57 employees as of Jul 26. Here is Triveni Bio's employee count trend over the years:

Uncover Triveni Bio's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Triveni Bio include BeiGene, Biogen and argenx. Here is the list of Top 10 competitors of Triveni Bio, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	80/100
2nd	Biogen 1978, Cambridge (United States), Public	Developer of therapies for neurodegenerative and immunology disorders	$80M	Berkshire Hathaway, Digital Pharma Lab & 11 others	78/100
3rd	argenx 2008, Ghent (Belgium), Public	Developer of antibody-based drugs to treat autoimmune diseases and cancer	$61.9M	Life Sciences Partners, Seventure Partners ... & 21 others	75/100
4th	Alexion 1992, Zurich (Switzerland), Acquired	Developer of therapies for patients with devastating and rare diseases	$133M	Allen & Company, Permira & 9 others	74/100
5th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
6th	Abcellera Biologics 2012, Vancouver (Canada), Public	AI-enabled platform for antibodies discovery	$115M	DCVC, Orbimed & 16 others	71/100
7th	BioNTech 2008, Mainz (Germany), Public	Developer of immunotherapeutics for the treatment of cancer and other diseases	$861M	Fidelity Investments, Redmile Group & 28 others	69/100
8th	Immunocore 2008, Abingdon (United Kingdom), Public	Developer of bispecific T cell receptor therapies for human diseases	$601M	General Atlantic, BlackRock & 50 others	69/100
9th	Nimbus Therapeutics 2009, Cambridge (United States), Series F	Developer of targeted therapeutics for cancer, metabolic and inflammatory diseases	$637M	BVF Partners, Atlas Venture & 20 others	68/100
10th	ADMA Biologics 2005, Ramsey (United States), Public	Biopharmaceutical company innovating plasma-derived therapeutics for immune deficiencies and infectious diseases	$17.6M	Aisling Capital, Burrill and Company & 4 others	68/100
68th	Triveni Bio 2023, Watertown (United States), Series C	Developer of functional antibodies for the treatment of immunological and inflammatory disorders	$272M	Goldman Sachs, Atlas Venture & 10 others	58/100